Summarized by Masters of Longevity from FierceBiotech - Biotech.
Novo’s strategic deal to acquire three early-stage obesity programs offers a closer look at its renewed metabolic focus and pipeline-building plans.
Key Takeaways
- A major pharmaceutical company purchased three early-stage obesity programs from New York biotech Kallyope.
- The acquired programs are focused on metabolic and obesity biology derived from gut-brain axis research.
- The deal expands the pharmaceutical company's early obesity pipeline and emphasizes renewed commitment to metabolic diseases.
